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Abstract
Objective: Vitamin D deficiency (VDD) in pregnant women and their children is an im-
portant health problem with severe consequences for the health of both. Thus, the ob-
jectives of this review were to reassess the magnitude and consequences of VDD during 
pregnancy, lactation and infancy, associated risk factors, prevention methods, and to 
explore epigenetic mechanisms in early fetal life capable of explaining many of the non-
skeletal benefits of vitamin D (ViD).
Data source: Original and review articles, and consensus documents with elevated level 
of evidence for VDD-related clinical decisions on the health of pregnant women and their 
children, as well as articles on the influence of ViD on epigenetic mechanisms of fetal 
programming of chronic diseases in adulthood were selected among articles published on 
PubMed over the last 20 years, using the search term VitD status, in combination with 
Pregnancy, Offspring health, Child outcomes, and Programming.
Data synthesis: The following items were analyzed: ViD physiology and metabolism, risk 
factors for VDD and implications in pregnancy, lactation and infancy, concentration cu-
toff to define VDD, the variability of methods for VDD detection, recommendations on 
ViD replacement in pregnant women, the newborn and the child, and the epigenetic 
influence of ViD.
Conclusions: VDD is a common condition among high-risk pregnant women and their chil-
dren. The routine monitoring of serum 25(OH)D3 levels in antenatal period is mandatory. 
Early preventive measures should be taken at the slightest suspicion of VDD in pregnant 
women, to reduce morbidity during pregnancy and lactation, as well as its subsequent 
impact on the fetus, the newborn and the child.
© 2014 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
*Corresponding author.
E-mail: urrutiamarilyn@gmail.com (M. Urrutia-Pereira).
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Deficiência de vitamina D na gravidez e o seu impacto sobre o feto, o recém-nascido 
e na infância
Resumo
Objetivo: Deficiência de vitamina D (DVD) nas gestantes e seus filhos é problema de 
saúde, com consequências graves à saúde de ambos. Assim, esta revisão visou reavaliar a 
magnitude e as consequências da DVD na gestação, lactação e infância, fatores de risco 
associados, métodos de prevenção, além de explorar os mecanismos epigenéticos na vida 
fetal capazes de explicar benefícios não-esqueléticos da vitamina D (ViD). 
Fonte de dados: Selecionaram-se artigos originais, de revisão e consensos com nível ele-
vado de evidência para decisões clínicas relacionadas à DVD na saúde das gestantes e 
seus filhos e artigos sobre sua ação sobre os mecanismos epigenéticos da programaçāo 
fetal de doenças crônicas na vida adulta, publicados no PubMed nos últimos 20 anos, 
empregando-se VitD status, e em combinaçāo com Pregnancy, Offspring health, Child 
outcomes e Programming. 
Síntese dos dados: Abordou-se fisiologia, metabolismo, fatores de risco para a DVD e 
implicações na gravidez, lactação e infância, concentração de corte para definir DVD, 
variabilidade de métodos na sua detecção, recomendações sobre a reposição de ViD nas 
gestantes, no recém-nascido e na criança, bem como sobre ter as influências epigenéti-
cas da ViD. 
Conclusões: DVD é frequente entre gestantes de alto risco e seus filhos. Monitorar 
rotineiramente os níveis séricos de 25(OH)D3 no período antenatal é imperativo. Medidas 
preventivas precoces devem ser instituídas à menor suspeita de DVD na gestante, para 
reduzir morbidades durante a gestação e a lactação, bem como seu posterior impacto 
sobre o feto, o recém-nascido e na infância. 
© 2014 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
Introduction
Vitamin D deficiency (VDD) is identified as a public health 
problem in many countries, and pregnant women have 
been identified as a high-risk group, among whom the prev-
alence of VDD ranges between 20 and 40%.1
While it is acknowledged that vitamin D (ViD) supple-
mentation is effective in preventing the VDD, many chil-
dren are born with this deficiency, raising questions as to 
how and why VDD affects the pregnancy, the fetus and the 
newborn’s health.2
The increase in the number of studies on this subject 
shows conflicting results on the association between 25(OH)
D levels in pregnancy and adverse effects on maternal and 
fetal health, both skeletal and non-skeletal (autoimmune 
diseases, cardiovascular diseases, diabetes and certain types 
of cancer through “fetal imprinting”).3 Thus, it is advisable 
to review VDD in mothers and their children so that strate-
gies can be implemented to prevent VDD in pregnancy and 
lactation, in order to prevent its impact on the fetus, the 
newborn and in childhood, aiming at a possible reduction in 
the future development of chronic diseases in adulthood.
Method
PubMed database was used for the selection of the arti-
cles used in this review, and the evaluated search period 
comprised the last 20 years. The following search terms 
were used: VitD status alone and in combination with the 
words: Pregnancy, Offspring health, Child outcomes, 
Programming. Among the identified studies, case reports 
and intervention studies without randomization were 
excluded. Original articles, review articles and consensus-
es with high level of evidence for clinical decisions relat-
ed to VDD regarding the health of pregnant women and 
their children were selected. Moreover, we selected arti-
cles that evaluated the influence of ViD in the epigenetic 
mechanisms of fetal programming of chronic diseases in 
adulthood, focusing on the latest works. The most rele-
vant articles according to the objectives of this review 
were therefore chosen.
Physiology and vitamin D metabolism
There are two sources of ViD for humans. An exogenous 
one is provided by the diet in the form of vitamins D2 
and D3. In the endogenous production, cholecalciferol 
(D3), the main source of ViD, is synthesized in the skin 
by the action of ultraviolet B (UVB) radiation through the 
photolysis of 7-dehydrocholesterol and transformed into 
vitamin D3. Sufficient exposure to sunlight or UVB radia-
tion is up to 18IU/cm2 in 3 hours. This process takes 
place in two phases: the first one occurs in the deep 
layers of the dermis and consists in the photo conversion 
of 7-dehydrocholesterol into pre-vitamin D or pre-calcif-
erol (Fig. 1).4
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In the second phase, there is a chemical isomerization 
depending on body temperature, and pre-vitamin D slowly 
and progressively turns into vitamin D3, which has high 
affinity for the ViD carrier protein (DBP), and the pre-vita-
min D, with lower binding affinity, remains in the skin.4 
Upon reaching the skin capillary network, ViD is transport-
ed to the liver and binds with DBP, where it starts its met-
abolic transformation.4
The two types of ViD undergo complex processing to be 
metabolically active.5 Initially, the pre-hormone is hydrox-
ylated in the liver at the carbon 25 position through the 
action of vitamin D-25-hydroxylase 1a (1-OHase), which 
constitutes an enzyme system dependent on cytochrome 
P-450 (CYP27B) present in liver microsomes and mitochon-
dria, and originates 25-hydroxyvitamin D (25(OH)D), the 
most abundant circulating form of ViD.4 Its mean blood con-
centration is 20-50ng/mL (50-125nmol/L) and it has an 
average life of approximately 3-4 weeks.4 It is estimated 
that its circulating pool is in dynamic equilibrium with 
reserves of 25(OH)D (muscle and adipose tissue), which 
makes blood levels a reliable indicator of the state of the 
ViD reserves in the body.4 Under normal circumstances, the 
percentage of conversion into 25(OH)D is low, with a distri-
bution of almost 50% in the fat and muscle compartments. 
When there is excess intake of ViD, most of it is stored in 
the fatty deposits.4
As 25(OH)D has low biological activity, it is transported 
to the kidney where it undergoes the second hydroxyl-
ation, and then the active forms are obtained: calcitriol 
(1a-dihydroxyvitamin D) (1.25(OH)2D) and 24.25-dihy-
droxyvitamin D (24.25(OH)2D), through the respective 
action of enzymes 1-OHase and vitamin D-24-hydroxylase 
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Figure 1 Synthesis and metabolism of vitamin D as well as its action on the regulation of levels of calcium, phosphorus and bone 
metabolism (Adapted from Holick MF.8).
UVB, ultraviolet light B; 25 (OH) D, 25-hydroxyvitamin D; 1,25 (OH) 2D, 1,25-dihydroxyvitamin D; 23-FGF, fibroblast growth factor 
23; Ca2 +, calcium ions; HPO42-, phosphorus ions.
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(24-OHase) present in mitochondria of cells of the proxi-
mal convoluted tubule.5
DBP and 25(OH)D are filtered by the glomerulus and 
absorbed in the proximal tubule by low-density lipoprotein 
receptors, which regulate the uptake of the 25(OH)D-DBP 
complex within the tubule cells and the subsequent hydrox-
ylation to 1.25(OH)2D.
4
1-OHase is also found in other tissues that express ViD 
receptors, such as the placenta, colon, activated mononu-
clear cells and osteoblasts, which could produce 1.25(OH)2D 
with local autocrine or paracrine function.6
Several factors regulate the levels of 1.25(OH)2D: 
1-OHase, whose hydroxylation is activated by the parathor-
mone (PTH), and calcitonin, which is inhibited by serum 
levels of calcium, phosphorus and 1.25(OH)2D itself, and 
whose average life is 15 days.6
Blood levels of phosphorus have a direct action, without 
the intervention of PTH, and hypophosphatemia increases 
the production of 1.25(OH)2D.
Thus, in addition to the main action of ViD in maintaining 
physiological levels of calcium and phosphorus capable of 
allowing metabolism, neuromuscular transmission and bone 
mineralization, the presence of ViD receptors in bone, bone 
marrow, cartilage, hair follicle, adipose tissue, adrenal 
gland, brain, stomach, small intestine, distal kidney tubule, 
colon, pancreas (B cells), liver, lung, muscle, activated B 
and T lymphocytes, heart cells, vascular smooth muscle 
cells, gonads, prostate, retina, thymus and thyroid glands 
has been described, which reinforce such diverse and 
important ViD functions (Fig. 2).5 Figure 3 summarizes the 
mechanisms involved in the control of serum calcium and 
phosphorus levels.7
Risk factors for ViD deficiency
The main source of ViD for children and adults is exposure 
to sunlight, so the main cause of VDD is the decrease of its 
endogenous production. Any factor that affects the trans-
mission of UVB radiation or interferes with its skin penetra-
tion will determine the reduction of 25(OH)D.4
Among these risk factors are:
• Use of sunscreen with a protection factor of 30 reduces 
the synthesis of ViD in the skin, above 95%
• Individuals with darker skin have natural sun protection, 
as melanin absorbs UVB radiation, and thus they need 
3-5 times longer sun exposure to synthesize the same 
amount of ViD than individuals with light skin
• Skin aging as well as age decrease the capacity of the 
skin to produce ViD due to lower availability of 7-dehy-
drocholesterol
• Skin damage such as burns decrease ViD production
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Figure 2 Non-skeletal functions of 1.25-dihydroxyvitamin D (Adapted from Holick MF.8).
VDR, vitamin D receptor; RXR, target region; 1-OHase, 25-hydroxyvitamin D-1a-hydroxylase; 25 (OH) D: 25-hydroxyvitamin D; 1,25 
(OH) 2D, 1,25-dihydroxyvitamin D; 24-OHase, 25-hydroxyvitamin D-24-hydroxylase; p21 and p27, genes involved in the control of 
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• Atmospheric contamination and overcast may act as sun-
screen
• The season of the year and the time of the day influence 
dramatically on the skin production of ViD
The second cause is the reduced intake of ViD, as few 
foods contain high quantities of it (blue fish, egg yolks). 
The intake of the vitamin can be increased with fortified 
products such as dairy products, although the amount of 
ViD they provide may be insufficient for an adequate state 
of ViD.8
Obesity can also be associated to VDD, because being a 
fat-soluble vitamin, ViD is sequestered by body fat. 
Another factor is the malabsorption of fats, as it occurs 
with the use of bile acid chelating agents (cholestyr-
amine), in cystic fibrosis, celiac disease and Crohn’s dis-
ease, among others.8 Also, anticonvulsants, glucocorti-
coids and drugs used in HIV treatment can lead to VDD by 
increasing the hepatic expression of cytochrome P-450 
and the catabolism of 25(OH)D. In severe liver failure, 
chronic granulomatous disease, certain lymphomas and 
primary hypoparathyroidism, patients have increased 
metabolism of 25(OH)D into 1.25 (OH)2D, and thus a high 
risk of VDD.8
Vitamin D deficiency in pregnancy and fetal 
programming 
During fetal life, the body tissues and organs go through 
critical development periods that coincide with periods of 
rapid cell division.9 Fetal programming is a process through 
which a stimulus or insult, during a certain development 
period, would have effects throughout life.10 This term is 
used to describe the mechanisms that determine fetal 
adaptation to changes that accompany the gene-environ-
ment interaction during specific periods of fetal develop-
ment.9
It has been demonstrated that nutritional and environ-
mental exposures during these sensitive periods of life may 
influence fetal growth and the development of physiologi-
cal functions of organs and systems. Permanent changes in 
many physiological processes of this programming can mod-
ify the expression patterns of genes, with consequent influ-
ence on phenotypes and functions (epigenetic mecha-
nisms).11
Thus, the closer to fertilization these changes take 
place, the greater the potential for epigenetic changes and 
their correspondence in newborns to occur in response to 
environmental changes. These changes in placenta/
embryo/fetus provide a plausible explanation for the con-
cept of fetal origin of adult diseases.12
It is currently recognized that nutrition in early life and 
other environmental factors play a key role in the patho-
genesis and predisposition to diseases, which seem to prop-
agate to subsequent generations. Epigenetic modifications 
establish a link with the nutritional status during critical 
periods of development and cause changes in gene expres-
sion that can lead to the development of disease pheno-
types.13
Recent evidence indicates that nutrients can modify the 
immune and metabolic programming during sensitive peri-
ods of fetal and postnatal development. Thus, modern 
diet patterns could increase the risk of immune and met-
abolic dysregulation associated with the increase of a 
wide range of noncommunicable diseases.11 Among these 
nutrients, ViD is emphasized, and its effects on fetal pro-
gramming and gene regulation might explain why it has 
been associated with many health benefits throughout 
life.8,14,15
There seems to be a window of early development in life 
that can shape the nature of the immune response in adult-
hood, and thus early life factors that predispose individuals 
to chronic lung disease would not be limited to the post-na-
tal period, as evidence indicates that there are intrauter-
ine effects such as maternal smoking, diet and ViD that 
influence the development of the lung and the subsequent 
development of asthma and chronic obstructive pulmonary 
disease.16,17
As much of the reprogramming that occurs during child-
hood may go unnoticed until adulthood, the better under-
standing of the interaction between genetics and epi-
genetics in critical time windows of development would 
improve our capacity to determine individual susceptibil-
ity to a wide range of diseases.13 Although these epigene-
tic changes appear to be potentially reversible, little is 
known about the rate and extent of improvements in 
response to positive environmental changes, including 
nutrition, and to what extent they depend on the duration 
of exposure to a deficient maternal environment also 
remains unknown.18
Thus, it can be observed that, in spite of all this new 
range of information, maternal nutrition has received lit-
Figure 3 Regulatory mechanisms of serum levels of calcium 
and phosphorus. Adapted from Ross AC et al.7
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tle attention in the context of implementation of effec-
tive prevention goals (MDG, Millennium Development 
Goals). This could be attributed to the lack of a solid and 
strong foundation to justify the enormous effort required 
to improve the nutritional status of all women of repro-
ductive age.19 To elucidate the true role of nutritional epi-
genetics13,14 in fetal programming of pregnant women, 
especially those with VDD, would allow the use of effec-
tive prevention measures to improve maternal and fetal 
health and prevent the development of future chronic dis-
eases.
Vitamin D and calcium metabolism 
in pregnancy
During pregnancy and lactation, significant changes in cal-
cium and ViD metabolism occur to provide for the needs 
required for fetal bone mineralization. In the first trimes-
ter, the fetus accumulates 2-3mg/day of calcium in the 
skeleton, which doubles in the last trimester.1
The pregnant woman’s body adapts to the fetal needs 
and increases calcium absorption in early pregnancy, reach-
ing a peak in the last trimester.1 The transfer is counterbal-
anced by increased intestinal absorption and decreased 
urinary excretion of calcium.
Plasma levels of 1.25(OH)2D increase in early pregnancy, 
reaching a peak in the third trimester and returning to nor-
mal during lactation. The stimulus for increased synthesis 
of 1.25(OH)2D is unclear, considering that PTH levels do not 
change during pregnancy.1
A potent stimulus to placental transfer of calcium and 
placental synthesis of ViD is the PTH-related peptide 
(PTHrP), produced in the fetal parathyroid and placental 
tissues, which increases the synthesis of ViD.1 The PTHrP 
can reach the maternal circulation and it acts through the 
PTH/PTHrP receptor in the kidney and bones, being a medi-
ator in the increase of 1.25(OH)2D and helping in the regu-
lation of calcium and PTH levels in pregnancy.1
Other signals involved in the regulation process include 
prolactin and the placental lactogen hormone, which 
increase intestinal calcium absorption, reduce urinary 
calcium excretion and stimulate the production of PTHrP 
and 1.25(OH)2D. Moreover, the increase in the maternal 
blood levels of calcitonin and osteoprotegerin protects 
the mother’s skeleton from excessive calcium resorp-
tion.1
Additionally, during lactation, there is a relative estro-
gen deficiency, caused by elevated levels of prolactin, 
which determines bone resorption and suppression of PTH 
levels. PTHrP levels are elevated and act as a substitute for 
PTH, while maintaining urinary calcium absorption and 
bone resorption.1
Implications of vitamin D deficiency 
in pregnancy
Recent studies emphasize the importance of non-classical 
roles of ViD during pregnancy and in the placenta and cor-
relate VDD in pregnancy with preeclampsia, insulin resis-
tance, gestational diabetes, bacterial vaginosis and 
increased frequency of cesarean delivery.20
ViD supplementation reduces the risk of preeclampsia. 
Studies in women with preeclampsia have shown low uri-
nary excretion of calcium, low ionized calcium levels, high 
levels of PTH and low levels of 1.25(OH)2D.
21 An association 
between maternal VDD (<50nmol/L) and increased risk of 
gestational diabetes (OR:2.66, 95% CI: 1.01 to 7.02),22 as 
well as the fact that VDD is an independent risk factor for 
bacterial vaginosis in pregnancy23 have also been docu-
mented. A recent randomized and controlled study showed 
that supplementation with 4,000IU/d during pregnancy was 
associated with reduced risk of combined morbidities, such 
as maternal infections, cesarean section and preterm deliv-
ery.21-24
A prospective study showed that cesarean delivery is four 
times more common in women with VDD (<37.5nmol/L) 
when compared to women with normal levels of ViD (OR: 
3.84, 95% CI: 1.71 to 8.62).25
Implications of vitamin D deficiency 
in lactation and childhood
Adequate levels of ViD are also important for the health of 
the fetus and the newborn, and poor skeletal mineraliza-
tion in utero due to VDD can be manifested in the newborn 
as congenital rickets, osteopenia or craniotabes.1
Maternal VDD is one of the main risk factors for VDD in 
childhood, as in the first 6-8 weeks of life newborns depend 
on the ViD transferred across the placenta while in the 
womb. This association is linear,26 and the 25(OH)D levels of 
the newborn correspond to 60-89% of maternal values .2
These levels decrease on the 8th week and, therefore, 
exclusively breastfed infants have an increased risk of VDD, 
as human milk has a low concentration of ViD (approxi-
mately 20-60IU/L; 1.5-3% of the maternal level). This con-
centration is not sufficient to maintain optimal levels of 
ViD, especially when exposure to sunlight is limited,27 and 
may induce seizures caused by hypocalcemia and dilated 
cardiomyopathy.1
Observational studies have shown that low levels of ViD 
during pregnancy and VDD in childhood are related to the 
increase in other non-skeletal manifestations,2 such as a 
higher incidence of acute lower respiratory tract infections 
and recurrent wheezing in the first five years of life.28
Contradictory results are observed in relation to the 
increased risk of allergic diseases such as asthma, eczema 
and rhinitis in the presence of VDD.29 However, a cohort 
study showed increased asthma and eczema among chil-
dren whose mothers had high serum levels of 25(OH)D 
during pregnancy.30
Japanese schoolchildren that received ViD supplementa-
tion (1,200IU/d) had a 42% reduction in the incidence of 
type A Influenza.1 A cohort study showed that supplementa-
tion with 2,000IU/d of ViD during the first year of life was 
associated with a reduction in the incidence of type I dia-
betes during a 30-year follow up.31
These results show the importance of maintaining ade-
quate levels of ViD in fetal life and in early life and child-
hood.
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Vitamin D deficiency, insufficiency 
and sufficiency 
The cutoff point to define the ViD status based on the val-
ues  of 25(OH)D is debatable. There are currently two crite-
ria:
• The Committee of the Institute of Medicine (IOM, USA)32 
considers values  lower than 20ng/mL (50nmol/L) as indi-
cators of VDD, with 10ng/mL (25nmol/L) being consid-
ered severe VDD, and 10-19ng/mL (25-49nmol/L) being 
considered ViD insufficiency. ViD levels <10ng/mL are 
associated with rickets and osteomalacia in adults and 
children. Between 10-19ng/mL, there is increased rate 
of bone resorption and increased risk of secondary hypo-
parathyroidism. Thus, the IOM recommends a threshold 
level of 20ng/mL as adequate to maintain bone health at 
all ages
• The Endocrine Society (USA) proposes VDD in the pres-
ence of ViD levels inferior to 20ng/mL and ViD insuffi-
ciency between 20-30ng/mL (50-75nmol/L).33 In clini-
cal practice, a patient would have sufficient levels 
when the concentration of 25(OH)D were greater than 
30ng/mL. Several authors support this concentration 
cutoff for musculoskeletal health and mineral metabo-
lism (prevention of rickets and osteomalacia, elevated 
PTH levels, osteoporotic fractures and falls among the 
elderly)34
The main differences between the IOM32 and the 
Endocrine Society33 are the overall health endpoints. The 
IOM makes recommendations to ensure skeletal health and 
suggests there is lack of evidence to support recommenda-
tions of potential non-skeletal benefits of ViD, considering 
that individuals with levels inferior to 20ng/mL  are not 
deficient, as 97% of individuals with these levels have ade-
quate bone health.32
The Endocrine Society33 considers that serum levels 
superior to 30ng/mL bring greater benefits to health in 
general, when compared to a level of 20ng/mL, and that 
skeletal health is not guaranteed with levels inferior to 
30ng/mL; these data are supported by three supposed 
observations:
• The increase in PTH reaches a plateau when serum 
25(OH)D is ≥30ng/mL; 
• There is a decrease in the risk of fractures in individuals 
with levels ≥30ng/ml;
• Calcium absorption is maximal for serum levels of 30ng/
mL.
Detection method
Serum levels of 25(OH)D are the best indicators of ViD 
status; however, methodological issues limit comparisons 
between studies, as well as the adoption of cutoffs to 
define hypovitaminosis D.4
Considering the method employed, it is important to ask: 
1) Does the method quantify the actual level of ViD? and 
2) Are these results reproducible and comparable between 
laboratories?4
Liquid Chromatography Coupled with Mass Spectrometry 
(LC-MS/MS) was recommended as the preferred method by 
the National Diet and Nutrition Survey.34 In general, all 
available methods are valid to detect severe VDD. As for 
moderate deficiency, there is a risk of error, which can be 
reduced by considering the reference values  of each labo-
ratory; however, for research studies, the methods 
employed should be standardized.6
Recommendations
If the main source of ViD comes from sunlight exposure, it 
is difficult to establish generalized requirements for the 
intake, especially due to the many variables associated 
with its deficiency.6
Table 1 shows the different recommended daily doses of 
ViD. Although the IOM recommends a daily intake of 200IU 
of ViD, this was insufficient to keep concentrations of 
25(OH)D above 50nmol/L.35 On the other hand, while rec-
ognizing that the exclusion of habitual sunlight exposure is 
a risk for VDD, it is unknown what level of exposure is safe 
and sufficient to maintain adequate levels of ViD.35 Table 2 
shows the different contents of ViD-fortified and 
non-ViD-fortified foods available for consumption in the 
United States. In Brazil, such data are scarce and most 
often do not reflect the content of all available processed 
foods.
In most countries, the monitoring of serum levels of 
25(OH)D during pregnancy is not performed; however, it is 
recommended that women with one or more risk factors for 
VDD be monitored in early and mid-pregnancy.36 
Consequently, the risk of VDD during pregnancy would be 
reduced, as well as the negative effects on the mother and 
the fetus; however, the appropriate dose of ViD supplemen-
tation for pregnant women to prevent VDD remains 
unknown.
Few studies have evaluated ViD supplementation in preg-
nancy, as well as the optimal levels to be offered. Several 
factors hinder the observation of an adequate dose-re-
sponse between low 25(OH)D levels and clinical outcomes: 
lack of data with extreme serum 25(OH)D levels and the 
wide variety of studied subjects (diversity of location, lat-
itude, season, ethnicity, body mass index, type of diet, 
lifestyle, skin pigmentation, family history of metabolic 
complications in pregnancy, physical activity and method 
used to quantify 25(OH)D).1
A meta-analysis of studies carried out in adults on ViD 
supplementation (2,000IU/d) and bone health showed 
that for each 1IU of vitamin D3 ingested, there is a corre-
sponding increase of 0.016nmol/L in serum levels of 
25(OH)D.37 Despite the limited evidence on the effects of 
ViD supplementation in pregnancy and the outcomes in 
the mother’s health and perinatal and early childhood 
effects, ViD supplementation (800-1,000IU/d) was accom-
panied by a protective effect in newborns with low birth 
weight.9,38
The Canadian Academy of Pediatrics (CAP)37 recommends 
supplementation with 2.000IU/d during pregnancy and lac-
tation.38 According to the American College of Obstetricians 
and Gynecologists,38 in the presence of VDD diagnosed 
during pregnancy, there should be supplementation with 
1.000-2.000IU/day of ViD.
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Studies have shown that maternal exposure during preg-
nancy to serum levels of 25(OH)D superior to 75nmol/L had 
no effect on the intelligence and psychological health of 
the children or on their cardiovascular system, but it could 
increase the risk of atopic diseases.30
In summary, ViD serum levels in pregnancy are a major 
concern, and the prevention of VDD in pregnant women and 
their newborns is vital and urgent.
Vitamin D recommendations for the newborn 
and children 
The Canadian Academy of Pediatrics defines ViD needs during 
the first year of life as 200IU/d for preterm newborns and 
400IU/d for other children. However, would the weight gain 
observed in the first year of life be accompanied by increased 
needs of ViD in a weight-dependent mode?38 Moreover, the 
CAP also recommends that infants and children be exposed to 
sunlight for short periods – probably less than 15 minutes.38
The American Academy of Pediatrics recommends that 
children who are exclusively breastfed should receive sup-
plementation with 400IU/day of ViD soon after birth and 
continue to receive during their development up to adoles-
cence.5 Concerned about the bone health of premature 
infants, they recommend biochemical monitoring of their 
25(OH)D levels during hospitalization, and recommend 200-
400IU/d of ViD, both during hospitalization and after dis-
charge.39,40 Recently, the IOM recommended 400IU/d for 
children younger than one year and 600IU/d for children 
aged between 1-8 years.32
Conclusion
VDD in pregnant women and their children is a major health 
problem, with potential adverse consequences for overall 
health. Prevention strategies should ensure the ViD suffi-
ciency in women during pregnancy and lactation. Evidence-
based interventions to improve maternal and fetal nutri-
tion, such as for ViD, are accompanied by a decrease of the 
impact on the health of their children.41
The ambiguities between the definitions of ViD status, 
combined with a lack of consistency in recommendations 
related to incorporation of routine testing of 25(OH)D lev-
els in the prenatal period, especially in women with risk 
factors for VDD, dose and gestational age for the start of 
ViD supplementation, universal cutoffs for normal ViD val-
ues, lack of education about the benefits of ViD and the 
need for adequate sunlight exposure represent important 
barriers to the advance of the implementation of ViD sup-
plemental guides, in order to improve this important health 
problem in pregnant women and their children in the short 
term. Large-scale studies in different geographical loca-
tions are necessary to identify the true role of ViD on the 
health of pregnant women and the “fetal imprinting” of 
their children.
Table 1 Dietary reference intakes and maximum tolerable intakes of vitamin D in different stages of life - IOM, 2010.32
Age Vitamin D mcg/day
AI EMR RDI MTI
Infants (0 to 6 months) 10 (400 UI) — —  25 (1,000 UI)
6 to 12 months 10 (400 UI) 15 (600 UI)  38 (1,520 UI)
13 months to 3 years — 10 (400 UI) 15 (600 UI)  63 (2,520 UI)
4 to 8 years — 10 (400 UI) 15 (600 UI)  75 (3,000 UI)
Men: 9 to 70 year — 10 (400 UI) 20 (800 UI) 100 (4,000 UI)
Women: 9 to 70 years — 10 (400 UI) 15 (600 UI) 100 (4,000 UI)
Age >70 years — 10 (400UI) 20 (800 UI) 100 (4,000 UI)
Pregnancy (14 to 50 years) — 10 (400 UI) 15 (600 UI) 100 (4,000 UI)
Lactation (14 to 50 years) — 10 (400 UI) 15 (600 UI) 100 (4,000 UI)
AI, intake adequate; EMR, estimated mean requirement; RDI, Recommended daily intake; MIT, maximum tolerable intake level; 
between brackets, the corresponding value in international units (IU).
Table 2 Dietary sources of vitamins D2  and D3. 
7
Source Vitamin D content
Salmon
Wild – 100g 600-1000UI de Vit D3
Bred in captivity – 100g 100-250UI Vit D3 ou D2
Canned – 100g 300-600UI Vit D3
Canned sardines – 100g ~300 UI Vit D3
Canned Horsetail – 100g ~250 UI Vit D3
Canned tuna – 100g ~230 UI Vit D3
Cod-liver oil (1 tbsp) ~400-1000 UI Vit D3
Fresh Shiitake mushroom – 100g ~100 UI Vit D3
Dried Shiitake mushroom – 100g ~1600 UI Vit D3
Egg yolk ~20 UI Vit D3 ou D2
Fortified foods
Fortified milk – 240mL ~100 UI Vit D3
Orange juice – 240mL ~100 UI Vit D3
Infant formulas – 240mL ~100 UI Vit D3
Fortified yogurts – 240mL ~100 UI Vit D3
Fortified butter – 100g ~50 UI Vit D3
Fortified margarine – 100g ~430 UI Vit D3
Fortified cheese – 85g ~100 UI Vit D3
Fortified morning cereals – meal ~100 UI Vit D3
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